Overweight Clinical Trial
Official title:
Safety Evaluation and Effect of Food Supplement Containing Dietary Fiber From Cassava on the Alterations of Physiological Parameters in Overweight Female Volunteers
This study is set up to determine the consumption safety and the effect of a food supplement containing dietary fiber from cassava on the alterations of physiological parameters including fasting blood sugar, HbA1c, insulin resistance, lipid profiles, atherogenic index, blood pressure and gut microbes in overweight female volunteers.
Cassava is one of the important industrial crops in Thailand. The leftover fiber of cassava
is still valuable and can be used as a dietary fiber. The previous study demonstrated that
dietary fiber containing cassava fiber was safe for consumption without any contamination of
the cyanide and heavy metals. Moreover, the microbial contaminations were within the safety
range. The toxicity study revealed that the LD50 of the cassava dietary fiber was more than 5
g/kg body weight (BW) and NOAEL was 3 g/kg BW. The NOAEL was used to calculate the human
equivalent dose for determining the effect of cassava dietary fiber in a clinical study.
Cassava dietary fiber consists of water-insoluble fiber such as cellulose more than 50%. The
previous study showed that insoluble fiber decreased the risk of type 2 diabetes and
increased insulin release. Moreover, a high fiber diet also decreased the fasting glucose and
HbA1C in type 2 diabetes volunteer. In addition, the effect of dietary fiber on the reduction
of cholesterol was also reported. The previous study reported that the cassava dietary fiber
could decrease the total cholesterol, triglyceride but increase high-density lipoprotein in a
dyslipidemia rat model. Therefore, the cassava fiber might be the potential food supplement
for the control of blood sugar and lipid profiles in human. However, less scientific data
support the effect of cassava dietary fiber in human.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Terminated |
NCT03299881 -
Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss
|
N/A | |
| Completed |
NCT02805478 -
Fat-Associated Cardiovascular Organ Dysfunction
|
||
| Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
| Completed |
NCT03759743 -
Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject
|
N/A | |
| Completed |
NCT03610958 -
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
|
N/A | |
| Completed |
NCT03678766 -
CHARGE: Controlling Hunger and ReGulating Eating
|
N/A | |
| Completed |
NCT04430465 -
Effects of Wholegrains on Children's Health (KORN)
|
N/A | |
| Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
| Completed |
NCT05376865 -
Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers
|
N/A | |
| Completed |
NCT03625427 -
Effect of Palmitoleic Acid on C-reactive Protein
|
N/A | |
| Active, not recruiting |
NCT03435445 -
Online Platform for Healthy Weight Loss (POEmaS)
|
N/A | |
| Enrolling by invitation |
NCT05576116 -
Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics
|
N/A | |
| Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
| Active, not recruiting |
NCT06023095 -
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
|
Phase 1 | |
| Completed |
NCT03648892 -
Brain Dopamine Function in Human Obesity
|
Early Phase 1 | |
| Not yet recruiting |
NCT05751993 -
Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions
|
N/A | |
| Recruiting |
NCT02887950 -
Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause
|
N/A | |
| Terminated |
NCT02796144 -
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
|
Phase 4 | |
| Completed |
NCT02829229 -
Community-based Obesity Treatment in African American Women After Childbirth
|
N/A |